Market Cap 201.93M
Revenue (ttm) 56.65M
Net Income (ttm) -53.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -94.10%
Debt to Equity Ratio 1.26
Volume 147,000
Avg Vol 338,304
Day's Range N/A - N/A
Shares Out 26.43M
Stochastic %K 49%
Beta 1.16
Analysts Strong Sell
Price Target $11.17

Company Profile

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular sy...

Industry: Medical Devices
Sector: Healthcare
Phone: 763 416 2840
Fax: 763 416 2841
Address:
9201 West Broadway Avenue, Suite 650, Minneapolis, United States
1111tu
1111tu Apr. 24 at 4:45 PM
$CVRX Annual Shareholder Mtg at 10:00 CDT May 1. It’s an online event only.
1 · Reply
1111tu
1111tu Apr. 23 at 1:07 PM
$CVRX. Addresses patient population targeted by Benefit HF Trial. New HFSA Scientific Statement Provides Practical Guidance for Managing Heart Failure with Mildly Reduced Ejection Fraction | HFSA https://hfsa.org/new-hfsa-scientific-statement-provides-practical-guidance-managing-heart-failure-mildly-reduced
2 · Reply
1111tu
1111tu Apr. 22 at 8:02 PM
$CVRX Any ideas why management pre-announced Q1? I don’t recall them doing that previously. They understandably have pre-announced Q4 the past few years while they compiled full year results , but not Q1. Did they make a public presentation requiring the pre-announcement of financials? No presentation is posted on their IR Event webpage calendar.
1 · Reply
1111tu
1111tu Apr. 20 at 10:50 PM
$CVRX @MedDevice Mgmt has publicly disclosed that their highest volume cohort of 50 sites installs avg 19/yr. So approximately 240 implants in Q4 25. This means the remaining 202 sites had 238 implants. Therefore ~50% of sales were earned in the top 19 accounts and 50% outside the top 19. It also means that most of the sales territories outside of the those that cover the 19 accounts don’t sell enough product to cover their own salaries. Hykes said that the high volume accounts see less than 7% of their qualifying HF patients receive a Barostim. That said, I’m sure the reps know it, management knows it, and there’s nothing like pressure to focus attention to accounts where growth can happen. This is a binary proposition.
1 · Reply
focafoca99
focafoca99 Apr. 20 at 9:37 PM
$CVRX nominated Michael Dale for election to its board at the June 1 annual meeting.
0 · Reply
MedDevice
MedDevice Apr. 20 at 2:01 AM
$CVRX Not a margin expansion story, this is a growth story. Implant growth simply isn’t happening in the US on a same store sales basis. The reported increase in insurance prior authorization approval rates will be confirmed in the next quarter, 6 months into the new year, for outpatient claims.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 17 at 1:21 PM
$CVRX RSI: 28.71, MACD: -0.1255 Vol: 0.73, MA20: 8.43, MA50: 7.63 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MITornado
MITornado Apr. 14 at 1:40 PM
$CVRX lowball price here… 60 million revenue bare minimum this year if q1 looks this strong . 200 million valuation for a med device start up is absolutely awful.
1 · Reply
focafoca99
focafoca99 Apr. 13 at 3:40 PM
$CVRX expects first-quarter 2026 revenue of about $14.7 million to $14.8 million, up roughly 20%, with gross margin near 87%.
0 · Reply
MedDevice
MedDevice Apr. 13 at 1:34 AM
$CVRX based on CVRx posts to X, approximately 19% of revenue since 2023 (at a 1:1 ratio implant to revenue unit and a 29,000 average asp per earnings reports) has come from 14 accounts that have posted > than 10 implants. Approximately 6% of active implanting centers as of Q4 2025 are producing 19% of the revenue. Not an absolute timeframe or a total number of sites, but a solid number based on most of the available public information.
1 · Reply
Latest News on CVRX
CVRx, Inc. Investigated by the Portnoy Law Firm

Apr 9, 2026, 9:00 AM EDT - 16 days ago

CVRx, Inc. Investigated by the Portnoy Law Firm


CVRx, Inc. Earnings Call Transcript: Q4 2025

Feb 12, 2026, 4:30 PM EST - 2 months ago

CVRx, Inc. Earnings Call Transcript: Q4 2025


CVRx Kicks Off One Of The Largest Heart Device Trials In History

Jan 23, 2026, 12:33 PM EST - 3 months ago

CVRx Kicks Off One Of The Largest Heart Device Trials In History


CVRx, Inc. Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 6 months ago

CVRx, Inc. Earnings Call Transcript: Q3 2025


CVRx, Inc. Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 9 months ago

CVRx, Inc. Earnings Call Transcript: Q2 2025


CVRx Announces Positive News on Outpatient Payment for Barostim

Jul 16, 2025, 7:30 AM EDT - 10 months ago

CVRx Announces Positive News on Outpatient Payment for Barostim


CVRx, Inc. Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

CVRx, Inc. Earnings Call Transcript: Q1 2025


CVRx, Inc. Earnings Call Transcript: Q4 2024

Feb 4, 2025, 4:30 PM EST - 1 year ago

CVRx, Inc. Earnings Call Transcript: Q4 2024


CVRx, Inc. Earnings Call Transcript: Q3 2024

Oct 29, 2024, 4:30 PM EDT - 1 year ago

CVRx, Inc. Earnings Call Transcript: Q3 2024


CVRx announces new CPT® Category I codes for Barostim

Oct 18, 2024, 2:08 PM EDT - 1 year ago

CVRx announces new CPT® Category I codes for Barostim


CVRx Announces Appointment of Two New Board Members

Sep 3, 2024, 8:30 AM EDT - 1 year ago

CVRx Announces Appointment of Two New Board Members


CVRx, Inc. Earnings Call Transcript: Q2 2024

Jul 29, 2024, 4:30 PM EDT - 1 year ago

CVRx, Inc. Earnings Call Transcript: Q2 2024


CVRx, Inc. Earnings Call Transcript: Q1 2024

Apr 30, 2024, 5:00 PM EDT - 2 years ago

CVRx, Inc. Earnings Call Transcript: Q1 2024


CVRx, Inc. Earnings Call Transcript: Q4 2023

Jan 25, 2024, 4:30 PM EST - 2 years ago

CVRx, Inc. Earnings Call Transcript: Q4 2023


CVRx, Inc. Earnings Call Transcript: Q3 2023

Oct 26, 2023, 5:30 PM EDT - 2 years ago

CVRx, Inc. Earnings Call Transcript: Q3 2023


CVRx, Inc. Earnings Call Transcript: Q2 2023

Jul 25, 2023, 5:30 PM EDT - 2 years ago

CVRx, Inc. Earnings Call Transcript: Q2 2023


CVRx, Inc. Earnings Call Transcript: Q1 2023

Apr 27, 2023, 5:00 PM EDT - 3 years ago

CVRx, Inc. Earnings Call Transcript: Q1 2023


CVRx, Inc. Transcript: Preliminary Study Result

Mar 21, 2023, 4:30 PM EDT - 3 years ago

CVRx, Inc. Transcript: Preliminary Study Result


CVRx, Inc. Transcript: Preliminary Study Result

Feb 21, 2023, 9:00 AM EST - 3 years ago

CVRx, Inc. Transcript: Preliminary Study Result


CVRx, Inc. Earnings Call Transcript: Q4 2022

Jan 26, 2023, 5:30 PM EST - 3 years ago

CVRx, Inc. Earnings Call Transcript: Q4 2022


CVRx, Inc. Transcript: JPMorgan Healthcare Conference

Jan 11, 2023, 6:45 PM EST - 3 years ago

CVRx, Inc. Transcript: JPMorgan Healthcare Conference


CVRx, Inc. Earnings Call Transcript: Q3 2022

Nov 1, 2022, 5:30 PM EDT - 3 years ago

CVRx, Inc. Earnings Call Transcript: Q3 2022


CVRx, Inc. Earnings Call Transcript: Q2 2022

Jul 27, 2022, 9:22 PM EDT - 4 years ago

CVRx, Inc. Earnings Call Transcript: Q2 2022


CVRx, Inc. Earnings Call Transcript: Q1 2022

Apr 25, 2022, 3:26 PM EDT - 4 years ago

CVRx, Inc. Earnings Call Transcript: Q1 2022


1111tu
1111tu Apr. 24 at 4:45 PM
$CVRX Annual Shareholder Mtg at 10:00 CDT May 1. It’s an online event only.
1 · Reply
1111tu
1111tu Apr. 23 at 1:07 PM
$CVRX. Addresses patient population targeted by Benefit HF Trial. New HFSA Scientific Statement Provides Practical Guidance for Managing Heart Failure with Mildly Reduced Ejection Fraction | HFSA https://hfsa.org/new-hfsa-scientific-statement-provides-practical-guidance-managing-heart-failure-mildly-reduced
2 · Reply
1111tu
1111tu Apr. 22 at 8:02 PM
$CVRX Any ideas why management pre-announced Q1? I don’t recall them doing that previously. They understandably have pre-announced Q4 the past few years while they compiled full year results , but not Q1. Did they make a public presentation requiring the pre-announcement of financials? No presentation is posted on their IR Event webpage calendar.
1 · Reply
1111tu
1111tu Apr. 20 at 10:50 PM
$CVRX @MedDevice Mgmt has publicly disclosed that their highest volume cohort of 50 sites installs avg 19/yr. So approximately 240 implants in Q4 25. This means the remaining 202 sites had 238 implants. Therefore ~50% of sales were earned in the top 19 accounts and 50% outside the top 19. It also means that most of the sales territories outside of the those that cover the 19 accounts don’t sell enough product to cover their own salaries. Hykes said that the high volume accounts see less than 7% of their qualifying HF patients receive a Barostim. That said, I’m sure the reps know it, management knows it, and there’s nothing like pressure to focus attention to accounts where growth can happen. This is a binary proposition.
1 · Reply
focafoca99
focafoca99 Apr. 20 at 9:37 PM
$CVRX nominated Michael Dale for election to its board at the June 1 annual meeting.
0 · Reply
MedDevice
MedDevice Apr. 20 at 2:01 AM
$CVRX Not a margin expansion story, this is a growth story. Implant growth simply isn’t happening in the US on a same store sales basis. The reported increase in insurance prior authorization approval rates will be confirmed in the next quarter, 6 months into the new year, for outpatient claims.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 17 at 1:21 PM
$CVRX RSI: 28.71, MACD: -0.1255 Vol: 0.73, MA20: 8.43, MA50: 7.63 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MITornado
MITornado Apr. 14 at 1:40 PM
$CVRX lowball price here… 60 million revenue bare minimum this year if q1 looks this strong . 200 million valuation for a med device start up is absolutely awful.
1 · Reply
focafoca99
focafoca99 Apr. 13 at 3:40 PM
$CVRX expects first-quarter 2026 revenue of about $14.7 million to $14.8 million, up roughly 20%, with gross margin near 87%.
0 · Reply
MedDevice
MedDevice Apr. 13 at 1:34 AM
$CVRX based on CVRx posts to X, approximately 19% of revenue since 2023 (at a 1:1 ratio implant to revenue unit and a 29,000 average asp per earnings reports) has come from 14 accounts that have posted > than 10 implants. Approximately 6% of active implanting centers as of Q4 2025 are producing 19% of the revenue. Not an absolute timeframe or a total number of sites, but a solid number based on most of the available public information.
1 · Reply
1111tu
1111tu Apr. 6 at 9:11 PM
$CVRX $CVRX went from having ~15 posted open new hire positions last night to zero postings today.
1 · Reply
SuperGreenToday
SuperGreenToday Apr. 3 at 1:58 AM
$CVRX Share Price: $8.98 Contract Selected: Dec 18, 2026 $10 Calls Buy Zone: $0.64 – $0.79 Target Zone: $1.19 – $1.45 Potential Upside: 76% ROI Time to Expiration: 259 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MedDevice
MedDevice Mar. 30 at 12:10 PM
$CVRX “We are excited by the new data supporting Barostim being featured at THT 2026” So excited in fact, only the speaker made a private LinkedIn post about it. https://ir.cvrx.com/news-releases/news-release-details/cvrx-announces-late-breaking-data-and-scientific-presentations
0 · Reply
1111tu
1111tu Mar. 25 at 8:38 PM
$CVRX pg 2
0 · Reply
1111tu
1111tu Mar. 25 at 8:37 PM
$CVRX just posted this piece for ACC.
1 · Reply
MedDevice
MedDevice Mar. 24 at 1:52 PM
$CVRX ACC next week. Normally results in a move up based on booth curiosity in technology. Usually presents a good opportunity to capitalize on both sides of the trade. Will CVRx expand on the communicated results of the post market registry?
1 · Reply
MedDevice
MedDevice Mar. 23 at 2:47 AM
$CVRX based on last earnings call comments by the CFO regarding focus on going deeper in accounts and building programs, active implanting centers is not a relevant metric since this is measured as any center with 1 implant in the last 12 months. To gage salesforce optimization, leadership execution and program depth, active US sales territories and revenue per active territory is better measure of productivity and execution. With salesforce enhancements completed and narrowing of focus to going deeper, revenue per territory should increase without a substantial increase in active centers. Current territories in Q4 (53) is in range of the communicated 3-5 centers per territory (4.75).
0 · Reply
Felaw
Felaw Mar. 20 at 4:37 PM
$CVRX need to break 9.02
0 · Reply
BioGem
BioGem Mar. 15 at 8:46 PM
$CVRX I am adding to my short in the high $7's. All what I said previously stays true, and the short interest has rapidly gone up since then. This will tank big after the Q1 26 losses are posted. Insider buying does not change the poor fundamentals.
1 · Reply
MedDevice
MedDevice Mar. 11 at 9:26 PM
$CVRX THT late breaker update scheduled for 3/12 cancelled and X posts deleted by CVRx. If the late breaking info is worthy of a press release to Wall Street, aren’t the results as well?
1 · Reply
MedDevice
MedDevice Mar. 10 at 6:49 PM
$CVRX top line Q1 revenue, 255 active centers and a 31K asp = 1.86 implants per active center. Q1 2024 had 1.8 per active center. Where's the growth in this growth stock?
0 · Reply
MedDevice
MedDevice Feb. 28 at 10:30 PM
$CVRX 6 associate territory manager positions posted. Analysts and investors need clarification on this role and if "enhanced" talent is being recruited for these positions. A quick glance at profiles of those with this title appear to be nurses and others with limited to no selling experience. There are 5 territory manager positions posted, 3 in large Florida cities, 1 in San Diego and 1 in Detroit. Expansion roles? More "enhancement" to the sales organization? Turnover? Sales director role for the Northeast posted as well. The results havent supported growth being the reason for these roles. Until proven otherwise, must model other reasons as management has communicated the enhancements are complete.
2 · Reply